MediPharm Labs Sets Date to Report Third Quarter 2021 Financial Results
MediPharm Labs Corp. (OTCQX: MEDIF) will release its third-quarter financial results for the period ending September 30, 2021, on November 15, 2021, prior to market opening. The company will conduct a conference call and audio webcast at 8:30 a.m. ET the same day to discuss results and future outlook. MediPharm Labs specializes in pharmaceutical-grade cannabis products and has obtained a Pharmaceutical Drug Establishment Licence from Health Canada, making it the only North American company with a domestic Good Manufacturing License for cannabinoid extraction.
- Obtained a Pharmaceutical Drug Establishment Licence from Health Canada.
- First revenues generated from the Australian extraction facility in H1 2020.
- Global leader in cannabis extraction with commercial exports to Australia.
- None.
TORONTO, Nov. 10, 2021 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE:MLZ) (“MediPharm Labs” or the “Company”) a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it will release third quarter financial results for the three and nine month period ended September 30, 2021 before markets open on Monday, November 15, 2021.
MediPharm Labs executive management team will also host a conference call and audio webcast on Monday, November 15, 2021, at 8:30 a.m. eastern time to discuss the Company’s financial results and outlook.
Audio Conference Call Dial In Details:
Toll-free number: +1-833-502-0471 / International number: +1-236-714-2179 / Conference ID: 8053143
Participants are asked to dial in approximately 15 minutes before the start of the call.
Audio Webcast:
An audio webcast will be available in the Events section of the MediPharm Labs’ Investor Relations website https://ir.medipharmlabs.com/news-events or by visiting the following link here.
For those who are unable to participate on the live conference call and webcast, a replay will be available approximately one hour after completion of the call.
A replay of the audio webcast will be available after the call has ended until November 22, 2021 11:59 p.m. eastern time. Within North America dial +1-800-585-8367 or International dial +1-416-621-4642 outside North America using Conference ID: 8053143.
About MediPharm Labs Corp.
Founded in 2015, MediPharm Labs specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products utilizing a Good Manufacturing Practices certified facility with ISO standard-built clean rooms. MediPharm Labs has invested in an expert, research driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities with five primary extraction lines for delivery of pure, trusted and precision-dosed cannabis products for its customers. Through its wholesale and white label platforms, MediPharm Labs formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. As a global leader, MediPharm Labs has completed commercial exports to Australia and completed commercialization of its Australian extraction facility which generated its first revenues in H1 2020. MediPharm Labs Australia was established in 2017.
In 2021, MediPharm Labs received a Pharmaceutical Drug Establishment Licence from Health Canada, becoming the only company in North America to hold a domestic Good Manufacturing License for the extraction of natural cannabinoids.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION:
This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; the inability of MediPharm Labs to obtain adequate financing; the delay or failure to receive regulatory approvals; and other factors discussed in MediPharm Labs’ filings, available on the SEDAR website at www.sedar.com. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, MediPharm Labs assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change.
FAQ
When will MediPharm Labs (MEDIF) release its Q3 financial results?
What is the significance of the Pharmaceutical Drug Establishment Licence for MediPharm Labs?
What time is the conference call for MediPharm Labs' Q3 results?
